“In partnership with Eli Lilly & Company, the American pharmaceutical giant, AbCellera started clinical trials for the antibody on June 1st. The speed at which the drug discovery and development process happened—weeks instead of years—indicates “an opportunity to reevaluate how drugs are developed,” said Carl Hansen.”
Read full coverage on The New Yorker.